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Primary pulmonary hypertension is a well described but etiology and pathogenesis of primary pulmonary hyperten- 
poorly understood illness. It is a disease of the small sion. The areas involved include the cell biology of pulmo- 
muscular pulmonary arteries in which proliferative lesions nary vascular endothelial and smooth muscle cells, studies 
involving endothelial cells, smooth muscle cells and fihro- of integrins, endothelial surface charge, angiogenesis and 
blasts obstruct flow. Aggressive therapy with vasodilator growth factors, endothelial-derived vasoactive substances, 
drugs, especially calcium channel blockers, has improved the effects of shear and the role of coagulation at the 
the quality of life in a minority of patients; heart-lung endothelial surface. The future looks bright for under- 
transplantation is feasible for only a few. standing and treating this difficult and cryptic illness. 
Rapid developments in the study of vascular biology in 
the last several years are likely to provide insight into the 
(J Am Co11 CardiolI989;14:551-5) 
Historical Background 
Primary pulmonary hypertension was first described as a 
distinct clinical entity by Dresdale et al. in 1951 (1). They 
defined a disease, primarily of young women, 
in whom pulmonary artery pressure was mark- 
edly elevated for no apparent reason, result- 
ing in car pulmonale and death. The crucial 
features that distinguished this illness from 
other causes of pulmonary hypertension were 
that cardiac disorders and alveolar hypoventila- 
tion could be excluded, and some patients 
transiently responded to a vasodilator. Over the 
next 30 years, until the establishment of the 
simply the collection of small series of patients to establish 
the clinical and demographic features of the illness (3,4). 
It was discovered that patients presented late in the ill- 
ness. usually after a short symptomatic period, and survival 
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National Institutes of Health Registry for Primary Pulmo- 
nary Hypertension (2). the major effort with regard to 
understanding primary pulmonary hypertension involved 
time in the majority of patients was brief, aver- 
aging 2 to 5 years. Because the disease is rare, 
most reports were limited to a few patients 
each and therapeutic approaches were a matter 
of guesswork. Despite this limitation, enough 
cases were reported to establish reasonably 
well that treatment with oxygen and antiin- 
flammatory drugs, such as corticosteroids, has 
had no beneficial effect and there has been no 
marked response to anticoagulants, but some 
patients have responded to one of a variety of vasodilator 
drugs (4). 
This article is Dart of a series of articles celebrating 
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the 40th anniversar?, ofthe American College of Cardi- 
ology. The series attempts to set the stagefor thefuture 
by describing current state of the art management of 
selected major cardiovascular problems and the basic 
knowledge that will provide directions for advances in 
diagnosis and therapy. 
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Pathogenesis 
The pathogenesis of primary pulmonary hypertension is 
unknown. Clinicians and scientists alike have expressed 
fascination with this dramatic and rare illness. Postmortem 
examination of the lungs reveals a normal lung parenchyma 
with disease peculiarly limited to the small muscular pulmo- 
nary arteries (5,6). The pathologic lesions are characteristic, 
but they are not pathognomonic because they can be found 
in other conditions such as scleroderma and Eisenmenger’s 
syndrome (7). Theories of pathogenesis are scarce: the most 
prevalent theory has focused on vasoconstriction, but there 
has been little supporting clinical evidence. Little informa- 
tion exists on the inciting mechanism, susceptibility to the 
illness or ongoing mechanisms of cellular and humoral 
pathogenesis. Until recently, fundamental knowledge of 
vascular biology has simply not been available. and the 
vocabulary to describe the pathogcnesis of vascular lesions 
is just now being developed. Currently there is a rapid 
growth in the available information about the determinants 
of vascular behavior and on injury and repair in both 
systemic and pulmonary vessels. It appears that the ground- 
work finally exists to allow us to begin to understand this 
rare disease. 
Current State of the Art 
Clinical features. The clinical description of primary pul- 
monary hypertension seems relatively complete. The initial 
publication from the National Institutes of Health Registry 
(2). which describes the clinical characteristics of 187 pa- 
tients, seems to agree with previous reviews on the features 
of this illness (3,4). Primary pulmonary hypertension is a 
disease affecting women over men in a I .7: I ratio: 5% to 10% 
of cases are familial with exactly the same clinical features as 
those seen in sporadic cases. Genetic transmission in familial 
disease appears to be autosomal dominant with highly vari- 
able expression of disease among different families (8). The 
mean age at the time of diagnosis of sporadic primary 
pulmonary hypertension is approximately 36 years (range of 
I to 80). The time from onset of symptoms to diagnosis is 
approximately 2 years, and the time of survival after diag- 
nosis is approximately 2 to 5 years. There have also been 
cases of exceptional longevity, exceeding 20 years. 
Most patients present with shortness of breath (>90%) 
and loss of energy (>75%). Some patients have cough. 
hemoptysis. peripheral cyanosis. and they may have chest 
pain, probably due to ischemia of the right ventricle. At 
cardiac catheterization mean pulmonary artery pressure is 
usually about 60 mm Hg, and it is not clear that the level of 
pulmonary hypertension pressure correlates well with sur- 
vival. The pressures and flows that correlate best with a 
short survival time are elevated right atrial pressure (> I I 
mm Hg), a function of right ventricular performance, and 
low cardiac output (cardiac index c2.l). 
Approximately 30% of patients respond to vasodilator 
drugs and these patients tend to have a longer survival time. 
although every known vasodilator drug has been reported to 
have beneficial effects in isolated patients (1+12), the 
calcium channel blockers seem to have the greatest likeli- 
hood of efficacy. Continuous infusion of prostacyclin may 
also confer lasting benefit, although it is technically demand- 
ing (13). Whether the beneficial effects of calcium channel 
blockers occur primarily or fully through vasodilation is not 
clear. but in recent studies (14) it appears that high dose 
calcium channel blockade can cause dramatic unequivocal 
vasodilation in some patients. Daily doses in such cases may 
consist of up to 240 mg of nifedipine and up to 720 mg of 
diltiazem. 
Pathologic features. The pathologic lesions of primary 
pulmonary hypertension are well described but poorly un- 
derstood. Controversy exists whether there is one origin of 
primary pulmonary hypertension that exhibits multiple 
pathologic features, or whether there are two or more 
separate origins that lead to the same clinical syndrome 
(15-17). The most frequently encountered pathologic fea- 
tures m primary pulmonary hypertension are those of “plex- 
ogenic arteriopathy” in which there is concentric intimal 
fibroelastosis of small arteries, complex lesions called plex- 
iform lesions and associated small vascular dilations. Some 
patients have no plexiform lesions or concentric intimal 
fibrosis but manifest what appear to be recanalized throm- 
botic lesions in small pulmonary arteries. In the lesion called 
“eccentric intimal fibrosis,” the fibroelastosis is not concen- 
tric but bulges asymmetrically from one portion of the 
vascular lumen. This lesion has been strongly thought by 
some pathologists (18) to be related to small vessel throm- 
bosis with recanalization. 
Loyd ct al. (16) recently made a careful morphometric 
analysis of pathologic specimens from patients with familial 
primary pulmonary hypertension, in whom the pathogenesis 
of disease should be the same. They found an unpredicted 
coexistence of eccentric intimal fibrosis, isolated medial 
hypertrophy. concentric intimal fibrosis and plexiform le- 
sions within and among families. The correlation of the 
pattern and frequency of these lesions in families was weak 
and there was a great deal of variability within individuals 
among families. These data raise serious questions about the 
previous belief that the presence of eccentric intimal fibrosis 
points to a separate origin of microthrombotic or microem- 
bolic pulmonary hypertension. The possibility that the 
pathogenesis of primary pulmonary hypertension involves 
coagulation at the endothelial surface or secondary throm- 
bosis in situ as a result of low flow is not questioned. It 
appears to us that the etiology or etiologies of primary 
pulmonary hypertension will not be revealed from discus- 
sions based on our current understanding of pathologic 
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presentations. The pathobiology of the vascular wall is 
where understanding of this disease is likely to emerge. 
Puthogenesis 
Vasoconstriction. Current theories of the pathogenesis of 
primary pulmonary hypertension are few and unsupported 
by hard data. For many years vrrsocons~riction was viewed 
as the primary mechanism of disease. The reason is not clear 
because another disease of vasoconstriction. hypoxic pul- 
monary hypertension of high altitude, is not associated with 
intimal fibrosis and vascular obstruction but merely with 
medial hypertrophy (19). On the other hand. the lesions in 
primary pulmonary hypertension do resemble the end stage 
vascular lesions of systemic hypertension. The reactivity of 
the pulmonary vascular bed to hypoxia in patients with 
primary pulmonary hypertension appears to be blunted. but 
recent studies showing unequivocal vasodilation in response 
to calcium channel blockers certainly implicate vasocon- 
striction in the end stage of this illness. Ten percent of 
female patients with primary pulmonary hypertension 
have Raynaud’s syndrome, an illness of vasoconstriction 
(14,20). 
Excessive flow and pressure. Because Eisenmenger’s syn- 
drome, most often associated with patent ductus arteriosus 
or ventricular septal defect. is associated with irreversible 
pulmonary hypertension and the same plexiform lesions 
seen in primary pulmonary hypertension, it is appealing to 
speculate that excessive&M. ~ndp/-essltre in the pulmonary 
circulation cause the pathologic response. It has been dif- 
ficult to create good animal models of pulmonary overflow, 
although models made by implantation of a systemic artery 
into the pulmonary artery have been attempted with variable 
success. One difficulty in the study of primary pulmonary 
hypertension is that there is no good animal model, a 
deficiency that desperately needs to be corrected. Studies 
examining the effect of pressure and shear stress on vascular 
endothelium are likely to yield important insights: this is a 
new and exciting area of investigation (2 I). 
Catecholamine-induced injury. The aminorex epidemic 
(9) and isolated cases of primary pulmonary hypertension 
related to catecholamine-like drugs (22) permit the specula- 
tion that the pathogenesis of primary pulmonary hyperten- 
sion is related to susceptibility qf the ~~r.sc.rdrrt~rrc to COW 
ddanline ugents (23). How this association may occur is 
unknown. We recently made a preliminary examination of 
the pulmonary arteries from autopsy specimens of patients 
whose death resulted from pheochromocytoma and found 
what appears to be mild medial hypertrophy and endothelial 
hyperplasia (unpublished observations). Patients with pri- 
mary pulmonary hypertension may have some unusual sus- 
ceptibility to catccholamine-induced in.jury. and perhaps 
these patients also have increased susceptibility to shear 
stress in the pulmonary circulation. The association of liver 
cirrhosis and primary pulmonary hypertension may be due 
to catecholamines (24). Systemic vasodilation, increased 
cardiac output and wide pulse pressure are catecholamine- 
like features of severe cirrhosis. 
Coagulation at the endothelial surface. This is a current 
theory about the origin of primary pulmonary hypertension. 
The evidence is scant and inferential but intriguing (25). 
Thromboxane Bz was found to be elevated in the plasma of 
a patient with primary pulmonary hypertension (26). Acti- 
vated platelet aggregates and increased circulating beta- 
thromboglobulin have been found in patients with systemic 
sclerosis and pulmonary vascular disease (27). Data from 
one study (28) suggest that anticoagulation may benefit 
patients with primary pulmonary hypertension. Defective 
fibrinolysis has been found in one family with primary 
pulmonary hypertension (28). Finally, primary pulmonary 
hypertension was recently reported (29) in five hemophiliacs 
in whom factor VIII therapy was a mainstay of existence. 
Surely the surface of the endothelium and its interaction 
with the humoral and cellular elements of blood will yield 
answers about the mechanism of this illness, and it seems 
likely that the coagulation cascade will be involved in some 
way. 
New Developments in Vascular Biology 
Aided by molecular techniques, advances in vascular 
biology are occurring in so many areas that insights into 
primary pulmonary hypertension will soon emerge. As yet, 
there are no known direct links between these new lines of 
research and the pathogenesis of primary pulmonary hyper- 
tension. What follows will be a brief survey of the areas of 
current development. 
Proliferative lesions: role of platelet-endothelial interac- 
tions. The proliferative lesions in systemic arteries resulting 
in atherosclerosis should serve as a model for the study of 
the pulmonary circulation (30). The similarities between 
atherosclerotic lesions and the lesions of primary pulmonary 
hypertension arc numerous: these include smooth muscle 
hypertrophy and phenotypic conversion of smooth muscle 
cells. resulting in secretion of elastin and other fibrous 
elements. and hyperplasia of the intima. A great deal of 
insight related to angiogenic factors. especially platelet- 
derived growth factor and macrophage-derived factors, sup- 
ports the possibility that platelet-endothelial interactions or 
other interactions between endothelium and circulating cells 
may initiate the proliferative response seen in primary pul- 
monary hypertension (31). 
Tl~e d@renc~es between atherosclerosis in systemic ar- 
teries end the ohlirerrrtive lesion in the pulmona~ cirda- 
tion rrre certain!\’ sign&ant. The pulmonary circulation 
does not develop atherosclerotic lesion\ as such, although 
hypertensive main pulmonary arteries may eventually de- 
velop xlerotic plaques. Why the pulmonary circulation, 
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even at systemic levels of pressure, does not develop ath- 
erosclerotic lesions is surely an important clue. The one 
constant difference between the pulmonary circulation and 
the systemic circulation is the partial pressure of oxygen of 
the perfusing blood. The systemic arterial bed is highly 
oxygenated, whereas the pulmonary artery bed is hypoxic. 
Perhaps atherosclerosis in systemic vessels is enhanced by 
toxic oxygen radicals whose concentration is less in the 
pulmonary circulation. 
Role of heparin-heparan and heparanase enzymes in the 
control of pulmonary vascular morphology. This is a fasci- 
nating area. Heparin. in addition to having anticoagulant 
properties, is one of the most anionic biologic substances 
known. It is responsible in part for the negatively charged 
domains on the endothelial surface. Charge-related lung 
microvascular injury by endogenous polycationic substances 
is an area worthy of attention in regard to primary pulmo- 
nary hypertension (32). Heparin has an additional attribute 
of inhibiting smooth muscle proliferation and can inhibit the 
vascular remodeling associated with chronic hypoxic expo- 
sure (33). Heparanase enzymes secreted by activated mac- 
rophages and T lymphocytes may be involved in the athero- 
sclerotic process in systemic arteries by changing surface 
charge or the inhibitory effects of heparin (34). It is unknown 
whether similar events may occur in the pulmonary circula- 
tion during the development of primary pulmonary hyper- 
tension. The interaction of the endothelium and its underly- 
ing smooth muscle involves communication directing either 
vasoconstriction or vasodilation, as in the case of endothe- 
lial-derived relaxation factor. angiogenin and certainly other 
mediators as yet undiscovered. Elastogenic and other pro- 
liferative factors secreted from hypoxic pulmonary arteries 
have been found (35). and the nature and communication 
between cells by way of these mediators must influence the 
hypertrophic response to inciting stimuli. 
Abnormal cell adhesion: adhesive proteins. Rapid prog- 
ress has been made in understanding the interactions be- 
tween certain proteoglycans and cell surface receptors that 
result in cell adhesion (36). Abnormal cell adhesion is 
potentially an important problem in primary pulmonary 
hypertension because migrating cells in the media and intima 
may have altered adhesiveness to the underlying basement 
membrane or in cell/cell interactions. Adhesive proteins are 
present both in the extracellular matrix and in the blood. 
These adhesive proteins, called integrins. include thrombo- 
spondin. fibronectin. fibrinogen, von Willebrand’s factor and 
others. Each of these proteoglycans has an arginine- 
glycine-aspartic acid sequence called RGD as its recogni- 
tion site for cell receptors (37). It is clear from preliminary 
work that the interactions of cells with integrins influence 
vascular behavior including anchorage of cells. traction 
for cell migration across cells and clues for cell position 
and polarity. It is also likely that these adhesion proteins 
help control cell and tissue growth. It is conceivable that 
primary pulmonary hypertension involves an abnormality 
of the receptor sites of the cells of the vascular wall to 
integrins. 
Studies of endothelial and smooth muscle cells in culture 
taken from the lungs of patients with primayy pulmonary 
hypertension undergoing transplantation will he of interest. 
Characterization of the behavior of these cells both by 
standard cell techniques and by measuring molecular signals 
such as the messenger ribonucleic acid (RNA) of prolifera- 
tive substances is likely to give insight into the mechanisms 
of the vascular abnormality seen in primary pulmonary 
hypertension. 
Primary Pulmonary Hypertension: 
The Future 
In this brief overview. we have tried to outline the current 
state of knowledge with regard to primary pulmonary hyper- 
tension and to highlight a few exciting developments in 
vascular biology that might pertain to primary pulmonary 
hypertension. Because patients with this disease usually 
present near the end stage of their disease, it will be most 
useful if some agent of reversibility can be identified to 
benefit them. Otherwise, the present unsatisfactory clinical 
status quo will continue. Currently we are able to improve 
the quality of life in a minority of patients and perhaps 
increase their survival time. Organ transplantation for pri- 
mary pulmonary hypertension remains a dramatic therapy 
for a few patients, but the complications of lung rejection 
versus life-threatening infections. particularly with cytomeg- 
alovirus, make heart-lung transplantation a choice of last 
resort. 
Ear/v detection of primary pulmonary hypertension 
wortld be highly desirable. Recent developments in two- 
dimensional echocardiography with Doppler techniques to 
measure pulmonary artery pressure noninvasively are en- 
couraging (38). The logistic problem is that primary pulmo- 
nary hypertension is a rare disease, and it is not feasible to 
screen an entire population to detect a disease that occurs in 
I in I million patients. Thus, in the short run, we will 
continue to identify these patients late in their disease and 
will be able to offer them only the best palliative care that 
can be developed by clinical trials. Nonetheless, it seems 
certain that over the next few decades primary pulmonary 
hypertension will be understood at the cellular and molecu- 
lar level. We can, therefore. be optimistic about the future. 
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